Samer Alsaid: Warfarin Outcomes Reassessed Through COMBINE AF
Samer Alsaid, Cardiologist and Vascular Medicine Specialist, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JACC: Advances, adding:
“Some projects become more than just papers.
Three years ago, my first project at the TIMI Study Group began with a long-standing idea of Dr. Eugene Braunwald.
He had long recognized that we had one of the world’s largest collections of patients treated with warfarin from the pivotal atrial fibrillation trials—and a unique opportunity to answer questions that remain clinically relevant today, including whether there are patients for whom warfarin may still be a reasonable option, particularly where access to DOACs is limited.
Three years later, that work has culminated in two companion papers from the COMBINE AF collaboration, now published in JACC: Advances.
Dr. Braunwald mentored this work every step of the way—with calls, ideas, and thoughtful edits—until the very end.
Sadly, he did not live to see these papers published.
His mentorship, intellectual curiosity, and unwavering commitment to improving patient care will stay with me for the rest of my career.”
Title: Outcomes With Warfarin in Atrial Fibrillation: Individual Patient Data Analysis From Four Randomized Trials
Authors: Samer AlSaid, Eugene Braunwald, Elaine M. Hylek, Michael G. Palazzolo, Andrea Bellavia, Elliott M. Antman, Anthony P. Carnicelli, John W. Eikelboom, Christopher B. Granger, Manesh R. Patel, Lars Wallentin, Christian T. Ruff, Robert P. Giugliano
Read the full article on JACC: Advances.
Title: Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial Fibrillation
Authors: Samer Al Said, Andrea Bellavia, Eugene Braunwald, Elaine M. Hylek, Michael G. Palazzolo, Hwanhee Hong, Elliott M. Antman, Anthony P. Carnicelli, John W. Eikelboom, Christopher B. Granger, Manesh R. Patel, Lars Wallentin, Christian T. Ruff, Robert P. Giugliano
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 28, 2026, 03:50ZhiChao (David) Yang: MedicalBench Tests AI in Clinical Reasoning
-
Oct 28, 2026, 03:46Phillip Smith: Strengthening Partnerships and Connections in the Rare Disease and Hemophilia Communities
-
Oct 28, 2026, 03:42Ashley Bradley: Understanding Jalen Hurts’ Diagnosis: DVT and Venous Thromboembolism in Athletes
-
Oct 28, 2026, 03:39Gregory Denomme: Petz and Garratty’s Immune Hemolytic Anemias Third Edition
-
Oct 28, 2026, 03:38Ahmed Alotaibi: Monoclonal Antibodies Challenge Routine Pretransfusion Testing
-
Oct 28, 2026, 03:32Wolfgang Miesbach: Should Prophylaxis in Type 3 VWD Follow the Bleeding Phenotype?
-
Oct 28, 2026, 03:25Owen McCarty: Exploring Platelet Polyphosphates in Coagulation Under Flow
-
Oct 28, 2026, 03:19Arwa Z. Al-Riyami: Key Takeaways from the Blood Conference in Auckland
-
Oct 28, 2026, 03:14Kristopher Jonas: The Ethical Case for Compensated Plasma Donation